{
  "id": "5c701f4f7c78d69471000060",
  "type": "factoid",
  "question": "Which disease is Dasatinib used to treat?",
  "ideal_answer": "Patients with chronic myeloid leukemia",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/29515069",
    "http://www.ncbi.nlm.nih.gov/pubmed/26951627",
    "http://www.ncbi.nlm.nih.gov/pubmed/27374826",
    "http://www.ncbi.nlm.nih.gov/pubmed/26300669",
    "http://www.ncbi.nlm.nih.gov/pubmed/22068151",
    "http://www.ncbi.nlm.nih.gov/pubmed/28795321",
    "http://www.ncbi.nlm.nih.gov/pubmed/24718698",
    "http://www.ncbi.nlm.nih.gov/pubmed/21828123",
    "http://www.ncbi.nlm.nih.gov/pubmed/29121645"
  ],
  "snippets": [
    {
      "text": "Patients with chronic myeloid leukemia",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21828123",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Our results suggest that the characteristics of complete molecular response on dasatinib treatment may be similar to that achieved with imatinib, at least in patients with adverse disease features.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21828123",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Dasatinib as salvage therapy for steroid refractory and imatinib resistant or intolerant sclerotic chronic graft-versus-host disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22068151",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Dasatinib, a second-generation TKI with a well-established safety and efficacy profile in chronic myeloid leukemia patients, who are refractory or intolerant to imatinib, has also shown potent antifibrotic effects.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22068151",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Furthermore, two recent studies showed dasatinib to be effective in inhibiting the in vitro growth of cells from leukemia patients with c-Cbl RING finger and linker domain mutations",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24718698",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Thus we conclude that dasatinib may not be an appropriate therapy for leukemia patients with c-Cbl mutations",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24718698",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " With continuous dasatinib combined with chemotherapy, but no allogeneic hsct, our patient reached complete molecular remission and has been in complete molecular remission for more than 13 months.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26300669",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Minimal residual disease-based effect and long-term outcome of first-line dasatinib combined with chemotherapy for adult Philadelphia chromosome-positive acute lymphoblastic leukemia.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26951627",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": " We assessed the minimal residual disease (MRD)-based effect and long-term outcome of first-line incorporation of dasatinib (100 mg once daily) into chemotherapy alternatively for adults with Ph-positive ALL.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26951627",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This dasatinib-based protocol was effective for achieving a good quality molecular response and durable DFS in adults with Ph-positive ALL",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26951627",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "NKG2D gene polymorphisms are associated with disease control of chronic myeloid leukemia by dasatinib.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28795321",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "A recent study reported that treatment-free remission (TFR) of chronic myeloid leukemia (CML) after dasatinib (Das) treatment was significantly associated with natural killer (NK) cell proliferation in the peripheral blood.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28795321",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Mixed connective tissue disease with pulmonary hypertension developing in a chronic myeloid leukemia patient on dasatinib treatment]",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29515069",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "A 37-year-old woman was diagnosed with chronic phase chronic myeloid leukemia. Nilotinib treatment was initiated; however, it had to be discontinued due to an allergic reaction one month later, and dasatinib treatment was provided. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29515069",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Novel lung imaging biomarkers and skin gene expression subsetting in dasatinib treatment of systemic sclerosis-associated interstitial lung disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29121645",
      "beginSection": "title",
      "endSection": "title"
    }
  ],
  "concepts": [],
  "exact_answer": "Chronic myeloid leukemia, CML"
}